2.1. Analysis.
Comparison 2: Subgroup analysis: Effects on mortality up to day 28, Outcome 1: Subgroup analysis (type of antiplatelet agent): cyclooxygenase inhibitors or ADP receptor/P2Y12 inhibitors in participants with moderate to severe COVID‐19
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.